TB-500 vs Vasoactive Intestinal Peptide (VIP)
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
TB-500
TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous protein involved in cell migration, tissue repair, and inflammation regulation. It has shown significant healing properties in preclinical models across muscle, tendon, ligament, and cardiac tissue.
Full profileVasoactive Intestinal Peptide (VIP)
28-amino acid neuropeptide found throughout the CNS, gut, and immune system. Functions as a potent anti-inflammatory, vasodilator, and neurotrophic factor. Research applications include CIRS (Chronic Inflammatory Response Syndrome), pulmonary arterial hypertension, autoimmune conditions, and gut motility disorders. Intranasal administration is most studied for CIRS and neuroinflammatory conditions.
Full profile| TB-500 | Vasoactive Intestinal Peptide (VIP) | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Thymosin Beta-4, Tβ4, TB500 | VIP, vasoactive intestinal polypeptide, PHM-27 |
| Evidence | Preclinical only | Investigational (in trials) |
| Dosing range | 2mg–10mg mg, twice weekly (loading), weekly (maintenance) | 25mcg–100mcg mcg, Daily intranasal or 1–2x weekly subcutaneous |
| Administration | Subcutaneous injection, Intramuscular injection | Intranasal spray, Subcutaneous injection, Inhalation (nebulized) |
| Key side effects | Head rush / lightheadedness (transient), Lethargy at higher doses, Injection site discomfort, Nausea (rare) | Facial flushing, Transient hypotension, Nasal irritation (intranasal route), Tachycardia |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: TB-500 is preclinical only, while Vasoactive Intestinal Peptide (VIP) is investigational (in trials).
- Administration: TB-500 — Subcutaneous injection, Intramuscular injection; Vasoactive Intestinal Peptide (VIP) — Intranasal spray, Subcutaneous injection, Inhalation (nebulized).
- Dosing units differ: TB-500 is dosed in mg, Vasoactive Intestinal Peptide (VIP) in mcg — they operate at different scales.
- Frequency: TB-500 is typically twice weekly (loading), weekly (maintenance); Vasoactive Intestinal Peptide (VIP) is Daily intranasal or 1–2x weekly subcutaneous.
How each works
TB-500
TB-500 promotes healing by upregulating actin, which drives cell migration to injury sites. Animal studies show accelerated repair of muscle tears, tendon injuries, and corneal wounds. It also demonstrates anti-inflammatory properties and has been studied for cardiac tissue repair following ischemic injury.
Vasoactive Intestinal Peptide (VIP)
VIP activates VPAC1 and VPAC2 receptors coupled to cAMP, suppressing pro-inflammatory cytokines while promoting Th2 regulatory immune responses and Treg differentiation. In the CIRS/biotoxin illness framework pioneered by Shoemaker, VIP intranasal formulation demonstrates normalization of inflammatory markers and improvement in TGF-β, MSH, and VIP deficiency seen in CIRS patients. Pulmonary vasodilation effects have been studied for PAH.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.